Professor, Consultant Interventional Cardiology
Lund University
Lund, Sweden
Dr David Erlinge is Professor of Cardiology at Lund University, Sweden Prof Erlinge is an interventional cardiologist focusing on PCI with a clinical interest in acute coronary syndromes. He is chairman of the Swedish PCI register (SCAAR) member of the board of SWEDEHEART.
He has been involved in the developing and leading registry based randomized clinical trials (RRCT) from TASTE, IFR-SWEDEHEART, DETO2X and was the leader of the pharmaceutical RRCT VALIDATE-SWEDEHEART and the diagnostic vunerable plaque trial PROSPECT II.
No relationships to disclose
5-Year Data from the SWEDHART and DEFINE: What Is the Take-Home Message?
Saturday, March 9, 2024
9:57 AM – 10:05 AM ET
Saturday, March 9, 2024
10:29 AM – 10:36 AM ET
Saturday, March 9, 2024
1:45 PM – 2:05 PM ET
Saturday, March 9, 2024
4:05 PM – 4:30 PM ET
Registry-Supported Trial Operations
Saturday, March 9, 2024
4:45 PM – 5:55 PM ET
Saturday, March 9, 2024
2:10 PM – 2:20 PM ET
Update on DynamX Bioadaptor Trial Results: INFINITY-SWEDEHEART
Sunday, March 10, 2024
11:34 AM – 11:42 AM ET
Discussion: Is There a Role/Need for Bioresorbable and/or Bioadaptor Platforms?
Sunday, March 10, 2024
11:58 AM – 12:15 PM ET
Sunday, March 10, 2024
3:18 PM – 3:26 PM ET
Sunday, March 10, 2024
3:26 PM – 3:41 PM ET
ATHEROSCLEROSIS THERAPEUTIC OPTIONS AND MANAGEMENT
Sunday, March 10, 2024
5:00 PM – 6:30 PM ET
Panel Discussion: Atherosclerosis Therapeutic Options and Management
Sunday, March 10, 2024
6:12 PM – 6:30 PM ET
Global Collaborative Structured Evidence Collection | The European Experience
Tuesday, March 12, 2024
9:54 AM – 10:02 AM ET
Panel Discussion: Leveraging Real-World Evidence: Where Are We Now and What Lies Ahead?
Tuesday, March 12, 2024
10:02 AM – 10:30 AM ET